Abstract:Na Li, 1, 2 Liyuan Hao, 1, 2 Shenghao Li, 1, 2 Jiali Deng, 1, 2 Fei Yu, 1, 2 Junli Zhang, 3 Aiyu Nie, 1, 2 Xiaoyu Hu 2 1 Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China; 2 Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China; 3 Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, People's Republic of China Correspondence: Xiaoyu Hu, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-Er-Qiao Road, Chengdu, Sichuan Province, 610075, People's Republic of China, Email Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive liver disorder with a rising prevalence. It begins with lipid accumulation in hepatocytes and gradually progresses to Metabolic-associated steatohepatitis (MASH), fibrosis, cirrhosis, and potentially hepatocellular carcinoma (HCC). The pathophysiology of MASLD is complex and involves multiple factors, with oxidative stress playing a crucial role. Oxidative stress drives the progression of MASLD by causing cellular damage, inflammatory responses, and fibrosis, making it a key pathogenic mechanism. The Nuclear Factor Erythroid 2-Related Factor 2 / Heme Oxygenase-1 (Nrf2/HO-1) signaling axis provides robust multi-organ protection against a spectrum of endogenous and exogenous insults, particularly oxidative stress. It plays a pivotal role in mediating antioxidant, anti-inflammatory, and anti-apoptotic responses. Many studies indicate that activating the Nrf2/HO-1 signaling pathway can significantly mitigate the progression of MASLD. This article examines the role of the Nrf2/HO-1 signaling pathway in MASLD and highlights natural compounds that protect against MASLD by targeting Nrf2/HO-1 activation. The findings indicate that the Nrf2/HO-1 signaling pathway holds great promise as a therapeutic target for MASLD. Keywords: the NRF-2/HO-1 signaling pathway, antioxidants, anti-inflammatory, natural compounds, non-alcoholic fatty liver disease Graphical Non-alcoholic fatty liver disease (NAFLD) is a condition characterized by excessive fat accumulation in the liver, excluding alcohol and other specific causes of liver damage. 1 To more accurately reflect the metabolic basis of the disease, an international expert panel introduced a new term in 2020: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), which replaced the old term "Non-Alcoholic Fatty Liver Disease" (NAFLD). 2 In 2023, a multi-society Delphi consensus statement on the new nomenclature for fatty liver disease introduced the term Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and formally discontinued the use of NAFLD. 3 Based on disease progression, MASLD can be classified into four distinct stages: simple steatosis, Metabolic-Associated Steatohepatitis (MASH), fibrosis, and cirrhosis. 4 The clinical manifestations of MASLD are diverse, with the majority of patients being asymptomatic. However, some patients may report symptoms such as fatigue, discomfort in the right upper quadrant, hepatomegaly, acanthosis nigricans, and lipomas. 5 In more severe cases, symptoms like jaundice, loss of appetite, nausea, and vomiting may occur. 6 Furthermore, MASLD is closely associated with metabolic and systemic diseases such as cardiovascular disease, obesity, type 2 diabetes, and sarcopenia. These conditions are not only common complications of MASLD, 7–9 but may also exacerbate its progression, leading to further deterioration of the patient's condition. 10–12 MASLD has become the most common liver disease worldwide and is expected to be the leading cause of end-stage liver disease in the coming decades. 13,14 According to statistics, the global prevalence of MASLD ranges from 25% to 34%, with 30% in Europe, 35% in South and North America, and 29.29% in Asia. Notably, the prevalence in Southeast Asia is as high as 42%. 15–18 The mortality rate for individuals with MASLD is 1.6 times higher than that of the general population, 19–21 with an all-cause mortality rate of 12.60 per 1000 person-years, posing a significant public health crisis. 22 Among the management strategies for MASLD, weight loss is considered one of the most effective measures; however, patients often struggle to maintain long-term adherence in practice. 23,24 Pharmacological and surgical treatments have also been shown to improve patients' metabolic conditions and increase survival rates effectively. Commonly used m -Abstract Truncated-

Circular RNA RRM2 alleviates metabolic dysfunction-associated steatotic liver disease by targeting miR-142-5p to increase NRG1 expression

Inhibition of mmu_circ_0009303 improves metabolic dysfunction-associated steatotic liver disease by regulating lipid metabolism and oxidative stress

A read-through circular RNA RCRIN inhibits metabolic dysfunction-associated steatotic liver disease

Circular RNA Circube2k Promotes Hepatic Fibrosis Via Sponging Mir‐149‐5p/tgf‐β2 Axis

Circular RNA circPSD3 alleviates hepatic fibrogenesis by regulating the miR-92b-3p/Smad7 axis

Antagonizing circRNA_002581–miR-122–CPEB1 axis alleviates NASH through restoring PTEN–AMPK–mTOR pathway regulated autophagy

Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice

IDDF2024-ABS-0412 Intestinal NLRP3 Deficiency Aggravates MASLD Mice Via Reduced Butyrate Production

N6-methyladenosine-modified Circirf2, Identified by YTHDF2, Suppresses Liver Fibrosis Via Facilitating FOXO3 Nuclear Translocation.

CircLDLR acts as a sponge for miR-667-5p to regulate SIRT1 expression in non-alcoholic fatty liver disease

Long Noncoding RNA FLRL2 Alleviated Nonalcoholic Fatty Liver Disease Through Arntl‐Sirt1 Pathway

Long Non-Coding Rna Profiling In A Non-Alcoholic Fatty Liver Disease Rodent Model: New Insight Into Pathogenesis

Hepatic miR-149-5p upregulation fosters steatosis, inflammation and fibrosis development in mice and in human liver organoids.

Circrna Expression Pattern And Circrna-Mirna-Mrna Network In The Pathogenesis Of Nonalcoholic Steatohepatitis

Liver circadian genes are modulated by high fat feeding in mice: Investigation of microRNA-mediated mechanisms

Circrna_0046366 Inhibits Hepatocellular Steatosis by Normalization of PPAR Signaling

Circular RNAs: Rising stars in lipid metabolism and lipid disorders

PPARalpha-ERRalpha crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression

The NRF-2/HO-1 Signaling Pathway: A Promising Therapeutic Target for Metabolic Dysfunction-Associated Steatotic Liver Disease

Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS Output.

A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p/miR-320a and ABCA1/CPT1 axis